- $122.86bn
- $143.58bn
- $33.54bn
- 86
- 51
- 78
- 84
Annual cashflow statement for Medtronic, fiscal year end - April 25th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 29th | 2023 April 28th | 2024 April 26th | 2025 April 25th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3,630 | 5,062 | 3,784 | 3,705 | 4,691 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1,031 | 1,070 | 751 | 1,427 | 862 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -701 | -888 | -967 | -484 | -1,054 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 6,240 | 7,347 | 6,039 | 6,787 | 7,044 |
| Capital Expenditures | -1,355 | -1,368 | -1,459 | -1,587 | -1,859 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1,511 | -291 | -2,034 | -779 | -78 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,866 | -1,659 | -3,493 | -2,366 | -1,937 |
| Financing Cash Flow Items | -268 | 163 | -409 | -3 | -184 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4,136 | -5,336 | -4,960 | -4,450 | -4,361 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -547 | 121 | -2,171 | -259 | 934 |